ExpreS2ion Biotech – Moving into preclinical with the Nipah project

EXPRS2Analyst Comment08.10.2025, 16.19

Summary

We assess that ExpreS2ion Biotech's transition to preclinical development for the Nipah virus vaccine marks a significant milestone, supported by an €8 million Horizon Europe grant.
In our view, the Nipah virus's high lethality and epidemic potential underscore the importance of this vaccine project, as there are currently no approved treatments or vaccines available.
ExpreS2ion highlights the potential for government interest in strategic vaccine stockpiles due to the risk of bioterrorism, although no market size estimates have been publicly provided.
ExpreS2ion Biotechnologies leverages its ExpreS2 production platform and AdaptVac's VLP technology to advance vaccine development.

This content is generated by AI. You can give feedback on it in the Inderes forum.

ExpreS2ion yesterday announced that the VICI-Disease consortium (which ExpreS2ion is a part of) has finalized the selection of the lead vaccine candidate for its Nipah virus vaccine - a program funded by an €8 million Horizon Europe grant aimed at obtaining clinical proof-of-concept for a Nipah virus vaccine within four years.

This milestone marks the transition from the discovery phase to preclinical development, as the project now moves into GMP production of the Nipah G protein to support preclinical studies and the subsequent CTA submission.

The Nipah virus is highly lethal (case fatality rate of approximately 40–75%) and has epidemic potential. There are currently no approved treatments or vaccines available. ExpreS2ion has previously highlighted the potential for misuse of the virus (e.g., bioterrorism), which could motivate governments to establish strategic vaccine stockpiles. However, the company has not yet provided any public estimates of the potential market size.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company focused on the development of vaccines through its ExpreS2 production platform in combination with AdaptVac's VLP technology.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR agreement. Michael Friis, 16.18, 09-10-2025

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.